Immunotherapy Drugs Market To Reach $675.98 Billion By 2033

Immunotherapy Drugs Market Growth & Trends

The global immunotherapy drugs market size is estimated to reach USD 675.98 billion by 2033, registering a CAGR of 11.41% from 2026 to 2033, according to a new report by Grand View Research, Inc. The key factors contributing to the lucrative growth of the industry include increased awareness about chronic diseases including cancer, autoimmune diseases, inflammatory diseases, and infectious diseases, coupled with supportive government policies for drug approval. The rising adoption of targeted therapies for chronic disease treatment is expected to increase inclination toward immunotherapy drugs, thereby driving the industry during the forecast period.

For instance, in May 2022, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab) received U.S. approval for treating HER2-positive breast cancer. Other targeted immunotherapy drugs include Kadcyla (trastuzumab emtansine) and Tecentriq (atezolizumab). In June 2022, F. Hoffmann-La Roche Ltd. received EU approval for Tecentriq as an adjuvant treatment for NSCLC. In addition, developing healthcare infrastructure in low- and middle-income countries coupled with increased research & development by key players is anticipated to contribute to the industry growth. For instance, in December 2021, Novartis AG collaborated with BeiGene, Ltd. for ociperlimab (BGB-A1217), therefore expanding its R&D activities in immune-oncology.

In August 2021, Pfizer, Inc. shared positive results from phase 2b/3 clinical trial of ritlecitinib for treating alopecia areata. Moreover, the rise in the incidence of cancer cases worldwide is expected to drive the demand for immunotherapy drugs. As per Globocan reports, an estimated 19.3 million new oncology cases were diagnosed in 2020. Moreover, according to the European Society of Medical Oncology, cancer incidence in Europe is anticipated to rise by 21% between 2020 and 2040. Thus, approvals of various immunotherapy drugs for cancer treatment are predicted to increase industry growth.

 Request a free sample copy or view report summary: Immunotherapy Drugs Market Report

Immunotherapy Drugs Market Report Highlights

• Based on drug type, the monoclonal antibodies segment accounted for the largest share of 56.16% in 2025, driven by their clinical efficacy, high target specificity, and broad applicability across cancer and autoimmune indications.

• Based on indication, the cancer segment dominated the market, accounting for 88.42% of the revenue in 2025, driven by high cancer prevalence and widespread adoption of immune-based therapies.

• The North America immunotherapy drugs market dominated the global market, with a revenue share of 41.80% in 2025. This strong position is attributable to the high incidence of cancer and autoimmune diseases, which drives the need for effective treatments.

Immunotherapy Drugs Market Segmentation

Grand View Research has segmented the global immunotherapy drugs market based on drug type, indication, and region:

Immunotherapy Drugs Drug Type Outlook (Revenue, USD Million, 2021 - 2033)

• Monoclonal Antibodies

• Immunomodulator

• Vaccine

• Others

Immunotherapy Drugs Indication Outlook (Revenue, USD Million, 2021 - 2033)

• Cancer

• Autoimmune Diseases

• Infectious Diseases

• Others

Immunotherapy Drugs Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Immunotherapy Drugs Market

• Amgen Inc.

• Novartis AG

• AbbVie Inc.

• Pfizer Inc.

• F. Hoffmann-La Roche Ltd

• Johnson & Johnson Services, Inc.

• AstraZeneca

• GSK plc.

• Sanofi

• Bayer AG